ESMO 2023 Insights: "CodeBreak 300 Phase 3 Study - Sotorasib & Panitumumab in KRAS G12Cm mCRC" | VuMedi

ecancer

ESMO 2023 Insights: "CodeBreak 300 Phase 3 Study - Sotorasib & Panitumumab in KRAS G12Cm mCRC"

By ecancer FEATURING Filippo Pietrantonio

By ecancer FEATURING Filippo Pietrantonio

254 views

October 27, 2023

0 Comments

Login to view comments. Click here to Login